All In Biotech

Drug Trial Radar · NCT03690206

Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)

A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Glepaglutide in Patients With Short Bowel Syndrome (SBS)

Last checked: Nov 20, 2026Latest source record: Jul 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 106 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

106

Actual

Start

Oct 4, 2018

Primary completion

Jul 26, 2022

Study completion Jul 26, 2022

Sponsor

Lead sponsor
Zealand PharmaIndustry
Sponsor type
Industry
First posted
Oct 1, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the trial is to confirm the efficacy of glepaglutide in reducing parenteral support volume in patients with short bowel syndrome. Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.

Conditions

  • Short Bowel Syndrome

Interventions

  • glepaglutideDrug

    Glucagon-Like Peptide-2 (GLP-2) analog

  • PlaceboDrug

    Placebo for glepaglutide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Weekly Parenteral Support (PS) VolumeTime frame: 24 weeks

Locations

29 sites in 9 countries. Site status is shown where the registry gives one.

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • University of Chicago Children's Hospital

    Chicago, Illinois

  • Mayo Clinic College of Medicine

    Rochester, Minnesota

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Mount Sinai Hospital

    New York, New York

  • Cleveland Clinic

    Cleveland, Ohio

  • Vanderbilt University Medical Center, Nashville

    Nashville, Tennessee

  • UZ Leuven

    Leuven, Belgium

  • The Royal Alexandra Hospital

    Edmonton, Canada

  • Western University

    London, Canada

  • University Health Network - Toronto General Hospital

    Toronto, Canada

  • Aalborg University Hospital

    Aalborg, Denmark

  • Rigshospitalet

    Copenhagen, Denmark

  • Hôpital Beaujon

    Clichy, France

  • Centre Hospitalier Lyon-Sud

    Pierre-Bénite, France

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany

  • Universitätsklinikum Bonn

    Bonn, Germany

  • Universitätsklinikum Frankfurt - Med. Klinik I

    Frankfurt, Germany

  • Asklepios Kliniken Hamburg GmbH

    Hamburg, Germany

  • Universitätsmedizin Rostock

    Rostock, Germany

  • UMC Radboud Nijmegen

    Nijmegen, Netherlands

  • Wojewodzki Specjalistyczny Szpital im. M. Pirogowa w Lodzi

    Lodz, Poland

  • Solumed

    Poznan, Poland

  • Szpital Skawina sp. z o.o. im. Stanley Dudricka

    Skawina, Poland

  • St Mark's Hospital

    Harrow, United Kingdom

  • UCLH Foundation NHS Trust

    London, United Kingdom

  • Salford Royal NHS Foundation Trust

    Manchester, United Kingdom

  • University of East Anglia

    Norwich, United Kingdom

  • University Hospital Southampton NHS Foundation Trust

    Southampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.